The threat of action from lawmakers may have put a damper on pharma's tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois' Akorn, which is reportedly looking into a...
Story updated at 9:50 a.m. to reflect market activity.
NEW YORK (TheStreet) --aLeerink Swann raised its price target for Akorn to $40 Thursday, reiterating its "market perform" rating.
Shares of Akorn gained 0.6% to $39.22 in morning...
NEW YORK (TheStreet) -- A San Diego-based biopharmaceutical company is gaining international attention for an experimental Ebola treatment that just saved two lives.
Mapp Biopharmaceutical is that company. Although it might sound like it employs...
Akorn, Inc. (NASDAQ:AKRX)
Q2 2014 Earnings Conference Call
August 5, 2014 10:00 AM ET
Raj Rai - CEO
Tim Dick - CFO
Randall Stanicky - RBC Capital Markets
Traver Davis - Piper Jaffray
David Krempa -...
NEW YORK (TheStreet) -- Shares of Akorn Inc. are up 4.86% to $36 in pre-market trade after the pharmaceutical company won U.S. antitrust approval to buy specialty prescription drug company VersaPharm on condition it sell its rights to a...
Shares of Akorn (NASDAQ: AKRX) were up nearly 10 percent Tuesday around $36.50 following the release of a Needham note in which the price target for the company was raised from $30 to $40.
The note cited a "game changing" effect if Akorn...
Oops! Unable to complete your request. Please refresh your browser.
The article on this company has not been written yet. If you're the first person to write this article, it's a sure thing that you'll be credited as a Top Contributor. For tips on getting started, check out the sample article.
You may also be interested in articles related to Akorn (AKRX):